Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK-DLI in Patients After HLA-haploidentical HSCT
NCT01386619Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Jan 2004
- Primary completion
- Mar 2011
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of CD3-depleted/CD56+ selected natural killer cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more, sponsored by University Hospital Basel. Primary endpoints: Feasibility of NK-DLI production at Day 0 and Safety of NK DLI Infusion. Started Jan 2004; status: completed.
02
Drugs
CD3-depleted/CD56+ selected natural killer cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)lymphomaneuroblastoma
Beyond the preview
Go deeper on NCT01386619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386619.